Ruiling Xu

1.4k total citations
61 papers, 1.0k citations indexed

About

Ruiling Xu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Ruiling Xu has authored 61 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 13 papers in Cancer Research and 12 papers in Oncology. Recurrent topics in Ruiling Xu's work include Sarcoma Diagnosis and Treatment (7 papers), Liver Disease Diagnosis and Treatment (6 papers) and RNA modifications and cancer (5 papers). Ruiling Xu is often cited by papers focused on Sarcoma Diagnosis and Treatment (7 papers), Liver Disease Diagnosis and Treatment (6 papers) and RNA modifications and cancer (5 papers). Ruiling Xu collaborates with scholars based in China, United States and United Kingdom. Ruiling Xu's co-authors include Jill Deikman, Jo Anna Reems, Yujiang Fan, Xingdong Zhang, Jie Liang, Stanley Goldman, Simon A. Coupe, Yuanchang Zhao, Han De-wu and Huiwen Wu and has published in prestigious journals such as SHILAP Revista de lepidopterología, ACS Nano and PLoS ONE.

In The Last Decade

Ruiling Xu

61 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ruiling Xu China 19 457 203 119 103 101 61 1.0k
Yuting Wang China 18 462 1.0× 185 0.9× 105 0.9× 59 0.6× 61 0.6× 81 1.2k
Na Huang China 21 421 0.9× 135 0.7× 152 1.3× 112 1.1× 162 1.6× 73 1.4k
Yong Zhuang China 22 519 1.1× 147 0.7× 162 1.4× 95 0.9× 61 0.6× 75 1.4k
Mohammad Mehdi Yaghoobi Iran 19 442 1.0× 146 0.7× 76 0.6× 81 0.8× 59 0.6× 62 1.2k
Yong Jung Kang South Korea 22 679 1.5× 93 0.5× 98 0.8× 135 1.3× 88 0.9× 51 1.5k
Meifang Liu China 18 370 0.8× 111 0.5× 83 0.7× 70 0.7× 55 0.5× 49 1.0k
Peraphan Pothacharoen Thailand 24 709 1.6× 216 1.1× 148 1.2× 107 1.0× 65 0.6× 100 1.9k
Bo Lv China 19 429 0.9× 229 1.1× 59 0.5× 53 0.5× 51 0.5× 52 1.0k
Jingyu Wang China 19 553 1.2× 84 0.4× 73 0.6× 86 0.8× 70 0.7× 52 1.2k

Countries citing papers authored by Ruiling Xu

Since Specialization
Citations

This map shows the geographic impact of Ruiling Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruiling Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruiling Xu more than expected).

Fields of papers citing papers by Ruiling Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruiling Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruiling Xu. The network helps show where Ruiling Xu may publish in the future.

Co-authorship network of co-authors of Ruiling Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Ruiling Xu. A scholar is included among the top collaborators of Ruiling Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruiling Xu. Ruiling Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Zhang, Wenchao, Lin Qi, Zhongyue Liu, et al.. (2025). RFWD3 Reprograms Nucleotide Metabolism Through PHGDH to Induce Chemoresistance In Osteosarcoma. Advanced Science. 12(16). e2410937–e2410937. 6 indexed citations
3.
Liu, Binfeng, Wei Li, Chengyao Feng, et al.. (2025). PKMYT1 kinase ameliorates cisplatin sensitivity in osteosarcoma. Signal Transduction and Targeted Therapy. 10(1). 165–165. 1 indexed citations
4.
Yang, Jianfei, et al.. (2024). Cross-center Model Adaptive Tooth segmentation. Medical Image Analysis. 101. 103443–103443. 1 indexed citations
5.
Wang, Yuxiang, Jingyi Liu, Xiaowen Han, et al.. (2024). An injectable photocuring silk fibroin-based hydrogel for constructing an antioxidant microenvironment for skin repair. Journal of Materials Chemistry B. 12(9). 2282–2293. 9 indexed citations
6.
Xu, Ruiling, Chenbei Li, Hua Wang, et al.. (2024). Deep learning-based artificial intelligence for assisting diagnosis, assessment and treatment in soft tissue sarcomas. SHILAP Revista de lepidopterología. 2(2). 100069–100069. 2 indexed citations
7.
Qi, Lin, Haodong Xu, Ruiling Xu, et al.. (2024). Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma. Oncogene. 44(7). 427–438. 5 indexed citations
8.
Xu, Ruiling, et al.. (2024). Single-cell analysis of chemotherapy-resistant microenvironment identifies a chemo-response biomarker for pancreatic cancer. Journal of Gastrointestinal Oncology. 15(4). 1836–1846. 1 indexed citations
9.
Zhou, Chen, Ruiling Xu, Xiaowen Han, et al.. (2023). Metal-phenolic self-assembly shielded probiotics in hydrogel reinforced wound healing with antibiotic treatment. Materials Horizons. 10(8). 3114–3123. 46 indexed citations
10.
Geng, Xinyu, Ning Li, Ruiling Xu, et al.. (2023). BMSCs alleviate liver cirrhosis by regulating Fstl1/Wnt/β-Catenin signaling pathway. Heliyon. 9(11). e21010–e21010. 4 indexed citations
11.
Xu, Ruiling, et al.. (2023). 3D Models of Sarcomas: The Next-generation Tool for Personalized Medicine. PubMed. 4(2). 171–186. 10 indexed citations
12.
Wang, Hongyan, et al.. (2023). Comparison between traditional and new obesity measurement index for screening metabolic associated fatty liver disease. Frontiers in Endocrinology. 14. 1163682–1163682. 9 indexed citations
13.
Jiang, Yanan, Yang Gao, Ruiling Xu, et al.. (2023). From Phenomenon to Essence: A Newly Involved lncRNA Kcnq1ot1 Protective Mechanism of Bone Marrow Mesenchymal Stromal Cells in Liver Cirrhosis. Advanced Science. 10(21). e2206758–e2206758. 5 indexed citations
14.
Qi, Lin, Ruiling Xu, Wenchao Zhang, et al.. (2022). Comprehensive Profiling Reveals Prognostic and Immunogenic Characteristics of Necroptosis in Soft Tissue Sarcomas. Frontiers in Immunology. 13. 877815–877815. 12 indexed citations
15.
Zhang, Yaru, Ruiling Xu, Fanghao Wang, et al.. (2021). Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy. 35(5). 1057–1066. 20 indexed citations
16.
Liu, Jing, et al.. (2020). Identification of a TLR-Induced Four-lncRNA Signature as a Novel Prognostic Biomarker in Esophageal Carcinoma. Frontiers in Cell and Developmental Biology. 8. 649–649. 19 indexed citations
18.
Wang, Xianding, Ruiling Xu, Libo Yan, et al.. (2010). Adult Renal Sarcoma: Clinical Features and Survival in a Series of Patients Treated at a High-volume Institution. Urology. 77(4). 836–841. 20 indexed citations
19.
Xu, Ruiling, et al.. (2005). In vitro umbilical cord blood expansion resulting in unique CD34Bright cell population that engrafts in NOD/SCID mice. Biology of Blood and Marrow Transplantation. 11(2). 69–69. 1 indexed citations
20.
Deikman, Jill, et al.. (1998). Separation of cis elements responsive to ethylene, fruit development, and ripening in the 5′-flanking region of the ripening-related E8 gene. Plant Molecular Biology. 37(6). 1001–1011. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026